154
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Epigenomics May Begin To Explain In Vitro Differential Response To Hypomethylating Agents In MMR-D Hypermethylated Endometrial Cancer

ORCID Icon, , , , , , , ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon, , , ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, , & show all
Pages 283-292 | Received 25 Jan 2023, Accepted 24 Apr 2023, Published online: 22 May 2023

References

  • Xiang M , EnglishDP , KiddEA. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma. Gynecol. Oncol.152(3), 599-604 (2019).
  • Kandoth C , SchultzN , CherniackADet al. Integrated genomic characterization of endometrial carcinoma. Nature497(7447), 67 (2013).
  • van den Heerik ASVM , HorewegN , NoutRAet al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int. J. Gynecol. Cancer30(12), 2002-2007 (2020).
  • de Boer SM , PowellME , MileshkinLet al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol.20(9), 1273-1285 (2019).
  • Fiegl H , GattringerC , WidschwendterAet al. Methylated DNA collected by tampons - a new tool to detect endometrial cancer. Cancer Epidemiol. Biomarkers Prev.13(5), 882-888 (2004).
  • Multinu F , ChenJ , MadisonJDet al. Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. Gynecol. Oncol.156(3), 682-688 (2020).
  • Sangtani A , WangC , WeaverAet al. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. Gynecol. Oncol.156(2), 387-392 (2020).
  • Wentzensen N , Bakkum-GamezJN , KillianJKet al. Discovery and validation of methylation markers for endometrial cancer. Int. J. Cancer135(8), 1860-1868 (2014).
  • Retis-Resendiz AM , González-GarcíaIN , León-JuárezM , Camacho-ArroyoI , CerbónM , Vázquez-MartínezER. The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium. Clin. Epigenetics13(1), 116 (2021).
  • Farkas SA , SorbeBG , NilssonTK. Epigenetic changes as prognostic predictors in endometrial carcinomas. Epigenetics12(1), 19-26 (2017).
  • Zhou XC , DowdySC , PodratzKC , JiangSW. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol. Oncol.107 (1), 143-153 (2007).
  • Tao MH , FreudenheimJL. DNA methylation in endometrial cancer. Epigenetics5(6), 491-498 (2010).
  • Shameer K , KleeEW , DalenbergAK , KulloIJ. Whole exome sequencing implicates an INO80D mutation in a syndrome of aortic hypoplasia, premature atherosclerosis, and arterial stiffness. Circ. Cardiovasc. Genet.7(5), 607-614 (2014).
  • Kalari KR , NairAA , BhavsarJDet al. MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing. BMC Bioinformatics15(1), 224 (2014).
  • Cunningham SA , ChiaN , JeraldoPRet al. Comparison of whole-genome sequencing methods for analysis of three methicillin-resistant Staphylococcus aureus outbreaks. J. Clin. Microbiol.55(6), 1946-1953 (2017).
  • Guzman C , D’OrsoI. CIPHER: a flexible and extensive workflow platform for integrative next-generation sequencing data analysis and genomic regulatory element prediction. BMC Bioinformatics18(1), 363 (2017).
  • Zhang Y , LiuT , MeyerCAet al. Model-based analysis of ChIP-Seq (MACS). Genome Biol.9(9), R137 (2008).
  • Quinlan AR , HallIM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics26(6), 841-842 (2010).
  • Sun Z , BahetiS , MiddhaSet al. SAAP-RRBS: streamlined analysis and annotation pipeline for reduced representation bisulfite sequencing. Bioinformatics28(16), 2180-2181 (2012).
  • Matsuzaki K , DengG , TanakaH , KakarS , MiuraS , KimYS. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin. Cancer Res.11(24), 8564-8569 (2005).
  • Berg M , NordgaardO , KørnerHet al. Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A. PLOS ONE10(4), e0122391 (2015).
  • Kahn RM , GordhandasS , MaddyBPet al. Universal endometrial cancer tumor typing: how much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Cancer 125(18), 3172-3183 (2019).
  • Alves MKS , FerrasiAC , LimaVP , FerreiraMVP , deMoura Campos Pardini MI , RabenhorstSHB. Inactivation of COX-2, HMLH1 and CDKN2A gene by promoter methylation in gastric cancer: relationship with histological subtype, tumor location and Helicobacter pylori genotype. Pathobiology78(5), 266-276 (2011).
  • Usui G , MatsusakaK , ManoYet al. DNA methylation and genetic aberrations in gastric cancer. Digestion102(1), 25-32 (2021).
  • Shilpa V , RahulB , PremalataCS , PallaviVR , LakshmiK. Microsatellite instability, promoter methylation and protein expression of the DNA mismatch repair genes in epithelial ovarian cancer. Genomics104(4), 257-263 (2014).
  • Corces MR , GranjaJM , ShamsSet al. The chromatin accessibility landscape of primary human cancers. Science362(6413), eaav1898 (2018).
  • Shi X , RadhakrishnanS , WenJet al. Association of CNVs with methylation variation. NPJ Genom. Med.5(1), (2020).
  • Wei AH , DöhnerH , PocockCet al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N. Engl. J. Med.383(26), 2526-2537 (2020).
  • Kommoss S , McConechyMK , KommossFet al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann. Oncol.29(5), 1180-1188 (2018).
  • Stenzinger A , AllenJD , MaasJet al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer58(8), 578-588 (2019).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.